例えば、2023年3月1日、希少疾病の日（Rare Disease Day 2023）にちなみ、ブルーム症候群協会は、新しいブルーム症候群協会のロゴ入りTシャツを用いた募金啓発キャンペーンを開始しました。その主な目的は、ブルーム症候群を含むすべての希少疾患の認知を広め、ブルーム症候群に苦しむすべての家族を教育し支援することにあります。
ブルーム症候群の認知度が高まれば、臨床試験や研究資金の増加、官民双方からの投資を呼び込むことができます。より多くの資源が利用できるようになれば、標的療法や遺伝子に基づく治療法を含む新しい治療法の開発に対する需要も高まり、その結果、ブルーム症候群の管理がより良く強化されることになります。
地域別
• 北米
o 米国
o カナダ
メキシコ
• ヨーロッパ
o ドイツ
イギリス
o フランス
o スペイン
o イタリア
o その他のヨーロッパ
• 南アメリカ
o ブラジル
o アルゼンチン
o その他の南米諸国
• アジア太平洋
o 中国
o インド
o 日本
o オーストラリア
o その他のアジア太平洋地域
• 中東およびアフリカ
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Demand for Innovative Therapeutics
4.1.1.2. Rising Awareness and Improved Management
4.1.2. Restraints
4.1.2.1. Side Effects Associated with Treatment
4.1.3. Opportunity
4.1.3.1. Technological Advancements in Therapeutic Options
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Antibiotics *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Proton Beam Therapy
7.4. Genetic Counseling
7.5. Speech Therapy
7.6. Occupational Therapy
7.7. Physical therapy
7.8. Others
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. U.K.
9.3.5.3. France
9.3.5.4. Spain
9.3.5.5. Italy
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Allergan Plc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Merck & Co., Inc.
11.3. Pfizer Inc.
11.4. GlaxoSmithKline plc
11.5. Abbott Laboratories
11.6. F. Hoffmann-La Roche Ltd.
11.7. Teva Pharmaceutical Industries Ltd.
11.8. Sanofi
11.9. Novartis AG
11.10. Sun Pharmaceutical Industries Ltd.
12. Appendix
12.1. About Us and Services
12.2. Contact Us
